CASE REPORT

Disseminated *Mycobacterium chimaera* infection in a patient with adult-onset immunodeficiency syndrome: case report

Yi-Fu Lin¹, Tai-Fen Lee², Un-In Wu¹,³, Chun-Fu Huang¹, Aristine Cheng¹, Kuan-Yin Lin¹* and Chien-Ching Hung¹,⁴

Abstract

**Background:** Patients with adult-onset immunodeficiency syndrome due to anti-interferon-γ autoantibodies (AIGAs) are susceptible to disseminated *Mycobacterium avium* complex (MAC) infections. *M. chimaera*, a newly identified MAC species, is distinguished from the others due to the reduced virulence. Previous cases of disseminated *M. chimaera* infection have been linked to cardiothoracic surgery. Reports of disseminated *M. chimaera* in patients without a history of cardiothoracic surgery are rare.

**Case presentation:** A 57-year-old Asian man, previously healthy, presented with fever, dry cough, exertional dyspnea, and decreased appetite. The delayed resolution of pneumonia despite antibiotic treatment prompted further imaging studies and biopsies from the lung and lymph node. The fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) demonstrated intense uptake in lung consolidations and diffuse lymphadenopathy. Cultures of the specimens obtained from sputum, blood, stool, lung tissue, and lymph node grew *M. chimaera*. Further immunological evaluation disclosed the presence of neutralizing AIGAs, which possibly led to acquired immunodeficiency and disseminated *M. chimaera* infection.

**Conclusions:** We herein present the first case of adult-onset immunodeficiency due to AIGAs complicated with disseminated *M. chimaera* infection. Further immunological evaluation, including AIGAs, may be warranted in otherwise healthy patients who present with disseminated mycobacterial infection.

**Keywords:** Anti-interferon-γ antibodies, Genetic predisposition, Immunosuppression, Non-tuberculous mycobacteria, *Mycobacterium avium* complex

Background

Adult-onset immunodeficiency syndrome due to anti-interferon-γ autoantibodies (AIGAs) is associated with susceptibility to selective infections [1]. Previous studies demonstrated that a high proportion of infections in patients with AIGAs were caused by mycobacteria (85.5%); among them, *Mycobacterium avium* complex (MAC) and *M. abscessus* were most commonly reported [2]. Disseminated MAC infection characteristically affects immunocompromised patients; however, *M. chimaera* is a newly described slow-growing non-tuberculous mycobacterium (NTM) belonging to the MAC and distinguished from the other MAC species due to the relatively reduced virulence. *M. chimaera* has been reported to cause pulmonary infection, recently linked to infections after cardiothoracic surgery and outbreaks attributed to contaminated
heater-cooler devices (HCDs) [3, 4]. The clinical presentations of *M. chimaera* infection include pulmonary diseases and extrapulmonary manifestations, including surgical site infection, prosthetic valve endocarditis, vascular graft infection, arthritis, osteomyelitis, and disseminated infection [5]. Although disseminated MAC infection disproportionally affects immunocompromised hosts, disseminated *M. chimaera* infection has more commonly occurred in patients undergoing cardiothoracic surgery and rarely been reported in patients with immune dysfunction [4, 6, 7]. We herein report the first case of adult-onset immunodeficiency due to AIGAs complicated with disseminated *M. chimaera* infection.

**Case presentation**

A 57-year-old Malaysian Chinese man, previously healthy, presented to our hospital with fever and exertional dyspnea for 1 week. One month before the current presentation, he developed dry cough and progressively decreased appetite. He had undergone appendectomy in his childhood but had no other systemic disease. There was no known family history of immunodeficiency or exposure to immunosuppressants before disease onset. On assessment, he was hemodynamically stable with the heart rate of 111 beats per minute, the blood pressure 106/60 mmHg, the respiration 18 breaths per minute, and the temperature 38.4°C. Physical examination revealed decreased breath sounds on the left lung and a swollen lymph node in the right neck. Laboratory evaluations showed leukocytosis (18,690 cells/μL) with neutrophilia (89%), anemia (7.9 g/dL), thrombocytosis (736,000 cells/μL), elevated C-reactive protein (15.81 mg/dL) with neutrophilia (89%), anemia (7.9 g/dL), thrombocytosis (736,000 cells/μL), elevated C-reactive protein (15.81 mg/dL), and elevated alkaline phosphatase (145 U/L). Physical examination revealed decreased breath sounds on the left lung and a swollen lymph node in the right neck. Laboratory evaluations showed leukocytosis (18,690 cells/μL) with neutrophilia (89%), anemia (7.9 g/dL), thrombocytosis (736,000 cells/μL), elevated C-reactive protein (15.81 mg/dL) with neutrophilia (89%), anemia (7.9 g/dL), thrombocytosis (736,000 cells/μL), elevated C-reactive protein (15.81 mg/dL), and elevated alkaline phosphatase (145 U/L). A chest radiograph and computed tomography (CT) demonstrated multifocal patchy consolidations, bilateral pleural effusion, and enlarged subcarinal lymph nodes (Fig. 1A). A pleural fluid analysis showed neutrophil-predominant exudates.

Ceftriaxone was administered intravenously at a dose of 1000 mg twice daily for 10 days, but his clinical condition and chest radiographs did not improve. The delayed resolution of pneumonia prompted a sonography-guided lung biopsy, in which pathology disclosed granulomatous inflammation with the presence of acid-fast bacilli (Fig. 1B and C). Colonoctomy showed multiple shallow cecal ulcers. The fluorodeoxyglucose-positron emission tomography/CT (FDG-PET/CT) for assessing the extent and severity of disease activity demonstrated intense uptake in lung consolidations and lymph nodes at bilateral supraclavicular, bilateral mediastinal, left para-sternal, and right mesenteric regions (Fig. 1D). Subsequently, the cultures of specimens obtained from sputum, blood, stool, lung tissue, and cervical lymph node revealed *M. chimaera*. A diagnosis of disseminated *M. chimaera* infection was made, and he was initially treated with amikacin (750 mg infusion once daily), rifabutin (300 mg orally once daily), azithromycin (500 mg orally once daily), and ethambutol (800 mg orally once daily). Three days after initiation of anti-mycobacterial therapy, the low-grade fever, leukocytosis, and elevated alkaline phosphatase persisted; and therefore, moxifloxacin (400 mg orally once daily) was added to the treatment regimen. The results of antimicrobial susceptibility testing are summarized in Additional file 1.

The investigations of immune deficiency showed no evidence of human immunodeficiency virus (HIV) infection, elevated immunoglobulin G (IgG) levels, and normal counts of lymphocyte subsets and monocyte. He had a high anti-nuclear antibody titer of 1:1280 with a fine speckled pattern, but did not meet the criteria of autoimmune diseases due to the absence of associated symptoms and specific extractable nuclear antigens. He tested positive for neutralizing AIGAs, with a plasma concentration of 901 μg/ml (reference value, 15.78 μg/ml). The methodologic details on AIGAs enzyme-linked immunosorbent assay (ELISA) are shown in Additional file 1. The patient carried the human leukocyte antigen (HLA) risk alleles (HLA-DRB1*16:02, HLA-DQB1*05:02), which were recently recognized to confer genetic predisposition to AIGAs production in populations originated from Southeast Asia [8]. His symptoms resolved gradually during subsequent follow-up, and the chest CT and colonoctopy one month later showed significant improvement in the consolidations and healing ulcers, respectively. Amikacin, rifabutin, and azithromycin were subsequently discontinued 1, 2, and 4 months later, respectively. As of 30 June, 2022, he had received ethambutol and moxifloxacin for 7 months. Since the follow-up chest radiography and laboratory data showed significant improvement, FDG-PET/CT will be scheduled 12 months after anti-mycobacterial therapy to guide the treatment duration.

**Discussion and conclusions**

*Mycobacterium chimaera* has been shown to be of low virulence, but could cause pulmonary infection as a consequence of colonization to the airways in patients with immunodeficiency or pre-existing lung conditions [5].
Fig. 1 (See legend on previous page.)
The treatment outcomes of *M. chimaera* lung disease were reported to be suboptimal despite the combination use of long-term antimicrobial agents [9]. On the other hand, disseminated *M. chimaera* infection had been scarcely described until 2013, when the first two cases were reported in patients with prosthetic valve endocarditis and bloodstream infection due to *M. chimaera* after open-chest cardiac surgery. Afterwards, more cases were identified in the prolonged outbreak, which was linked to a source of contaminated water in HCDs connected to the cardiopulmonary bypass. The increased use of contaminated HCDs has led to HCD-associated *M. chimaera* outbreaks globally since 2015, with more than 120 cases of *M. chimaera* infections reported following cardiac surgery in the literature [10]. With a long latency period (median, 21 months) between cardiac surgery and symptoms, the mortality rate of post-cardiac surgery *M. chimaera* infection was remarkably high (50%) [11]. To evaluate the disease extent and detect recurrence, FDG-PET/CT imaging is a crucial diagnostic tool and should be considered early in patients with disseminated *M. chimaera* infection [12].

Apart from systemic infection caused by contaminated HCDs, only two cases developed disseminated *M. chimaera* infection attributable to their immunodeficiency (Table 1) [6, 7]. One patient received prednisolone and hydroxychloroquine for systemic lupus erythematosus, and the other patient underwent chemotherapy for diffuse large B-cell lymphoma. Although both cases had underlying immune dysregulation and received immunosuppressants, disseminated *M. chimaera* infection was successfully treated with prolonged courses of antibiotics. Considering a rare occurrence of disseminated *M. chimaera* infection in patients without a history of cardiothoracic surgery, investigations to identify immune deficiency was performed in our patient. Adult-onset immunodeficiency syndrome due to AIGAs has been extensively described in East Asian populations [2], which prompted testing for AIGAs in this case.

Despite geographically varied distribution of NTM species, the dominant NTM species resulting in disseminated infection among patients with AIGAs is MAC (30.7%) [2]. In addition to the main species of MAC (*M. avium* and *M. intracellulare*), new MAC species (*M. colombiense* and *M. mantenii*) have been reported to cause disseminated infection in patients with AIGAs [13–15]. *M. chimaera*, a recently identified species of MAC, has a lower virulence than the two original species of MAC [3]. We present the first case of disseminated *M. chimaera* infection in a patient with AIGAs; nevertheless, systemic infection caused by *M. chimaera* among patients with AIGAs may be under-diagnosed due to inaccessibility to AIGAs ELISA and identification of MAC species. To reduce misdiagnosis, the commercially available interferon-γ release assay (IGRA) could be used in the clinical setting without readily accessible AIGAs ELISA. An indeterminate IGRA result may indicate the presence of neutralizing AIGAs in a patient with disseminated NTM infection [16, 17].

The present case highlights that disseminated *M. chimaera* infection can also occur in patients with adult-onset immunodeficiency syndrome due to AIGAs. Early recognition and immunological evaluation in otherwise healthy patients who present with disseminated

| References/country | Age/gender | Underlying disease | Manifestations | IGRA testing | Treatment regimen | Treatment duration | Outcome |
|--------------------|------------|--------------------|----------------|--------------|-------------------|-------------------|---------|
| Moutsoglou et al. [6]/USA | 75/female | Systemic lupus erythematosus, receiving prednisone and hydroxychloroquine | Vertebral osteomyelitis; calf wound infection | Indeterminate | Clarithromycin, rifampin, ethambutol | Prolonged | Successfully treated |
| de Melo Carvalho et al. [7]/Portugal | 57/male | Diffuse large B-cell lymphoma, receiving R-CHOP | Bloodstream infection; bone marrow involvement; pneumonia; hepatosplenomegaly | Negative | Clarithromycin, rifabutin, ethambutol, moxifloxacin | 12 months | Successfully treated |
| Present case/Taiwan | 57/male | Adult-onset immunodeficiency syndrome due to anti-interferon-γ autoantibodies | Bloodstream infection; pneumonia; lymphadenopathy | NA | Amikacin, azithromycin, rifabutin, ethambutol, moxifloxacin | Prolonged | Successfully treated |

*R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone*
mycobacterial infection are essential to improving outcomes.

Abbreviations
AIGAs: Anti-interferon-γ autoantibodies; CT: Computed tomography; ELISA: Enzyme-linked immunosorbent assay; FDG: Fluorodeoxyglucose; HIV: Human immunodeficiency virus; HCDs: Heater–cooler devices; HLA: Human leukocyte antigen; IgG: Immunoglobulin G; IGRA: Interferon-γ release assay; MAC: Mycobacterium avium Complex; NTM: Non-tuberculous mycobacterium; PET: Positron emission tomography; SUV$_{\text{max}}$: Maximum standardized uptake value.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12879-022-07656-0.

Additional file 1. Supplementary material.

Acknowledgements
Not applicable.

Author contributions
YFL wrote the first draft of the manuscript, CFH assisted in the acquisition of data; TFL and UIW performed the laboratory analyses; UW, AC, and KYL directed this work and helped to analyze the data and performed substantive modifications for this case report; AC, KYL, and CCH reviewed and improved the case report. All authors read and approved the final manuscript.

Funding
No funding was received for this work.

Availability of data and materials
All data generated or analyzed during this study is included in this published article.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Written informed consent for publication was obtained from the patient.

Competing interests
All authors report that they have no competing interests.

Author details
1 Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, 7 Chung-Shan South Road, Taipei, Taiwan. 2 Department of Laboratory Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. 3 Department of Medicine, National Taiwan University Cancer Center, Taipei, Taiwan. 4 Department of Tropical Medicine and Parasitology, National Taiwan University College of Medicine, Taipei, Taiwan.

Received: 12 April 2022   Accepted: 28 July 2022
Published online: 01 August 2022

References
1. Cheng A, Holland SM. Anticytokine autoantibodies: autoimmunity trespassing on antimicrobial immunity. J Allergy Clin Immunol. 2022;149(1):24–8.
2. Shih HP, Ding JY, Yeh CF, Chi CY, Ku CL. Anti-interferon-γ autoantibody-associated immunodeficiency. Curr Opin Immunol. 2021;72:206–14.
3. Chen LC, Huang HN, Yu CJ, Chien JY, Hsuhe PR. Clinical features and treatment outcomes of Mycobacterium chimaera lung disease and antimicrobial susceptibility of the mycobacterial isolates. J Infect. 2020;80(4):437–43.
4. Hasse B, Hannan NM, Keller PM, Maurer FP, Sommerstein R, Merch D, et al. International Society of Cardiovascular Infectious Diseases guidelines for the diagnosis, treatment and prevention of disseminated Mycobacterium chimaera infection following cardiac surgery with cardiopulmonary bypass. J Hosp Infect. 2020;104(2):214–35.
5. Riccardi N, Monticelli J, Antontello RM, Lazzati R, Gabrielli M, Ferrarese M, et al. Mycobacterium chimaera infections: an update. J Infect Chemother. 2020;26(3):199–205.
6. Moutsoglou DM, Merritt F, Cumberl E. Disseminated Mycobacterium chimaera presenting as vertebral osteomyelitis. Case Rep Infect Dis. 2017;2017:9893743.
7. de Melo Carvalho R, Nunes AL, Sa R, Ramos I, Valente C, Saraiva da Cunha J. Mycobacterium chimaera disseminated infection. J Med Cases. 2020;11(2):35–6.
8. Ku CL, Lin CH, Chang SW, Chu CC, Chan JF, Kong XF, et al. Anti-IFN-γ autoantibodies are strongly associated with HLA-DR*15:02/16:02 and HLA-DQ*05:01/05:02 across Southeast Asia. J Allergy Clin Immunol. 2016;137(3):945–8.e8.
9. Moon SM, Kim SY, Jhun BW, et al. Clinical characteristics and treatment outcomes of pulmonary disease caused by Mycobacterium chimaera. Diagn Microbiol Infect Dis. 2016;86(4):382–4.
10. Sax H, Bloemberg G, Hasse B, Sommerstein R, Kohler P, Achermann Y, et al. Prolonged outbreak of Mycobacterium chimaera infection after open-chest heart surgery. Clin Infect Dis. 2015;61(1):67–75.
11. Lecocle E, Pian de Pontilly G, Mougari F, Benmansour H, Poisnel E, Janvier F, et al. Disseminated Mycobacterium chimaera following open-heart surgery, the heater-cooler unit worldwide outbreak: case report and minireview. Front Med (Lausanne). 2020;7:243.
12. Tan NY, Tarabochia AD, DeSimone DC, DeSimone CV, Wilson JW, Bagameri G, et al. Updated experience of Mycobacterium chimaera infection: diagnosis and management in a tertiary care center. Open Forum Infect Dis. 2021;8(8):ofab348.
13. Roerden M, Döffinger R, Barcenas-Morales G, Forchhammer S, Döbele S, Berg CP. Simultaneous disseminated infections with intracellular pathogens: an intriguing case report of adult-onset immunodeficiency with anti-interferon-gamma autoantibodies. BMC Infect Dis. 2020;20(1):828.
14. Poulin S, Corbeil C, Nguyen M, St-Denis A, Côté L, Le Deist F, et al. Fatal Mycobacterium colombiense/cytomegalovirus coinfection associated with acquired immunodeficiency due to autoantibodies against interferon gamma: a case report. BMC Infect Dis. 2013;13:24.
15. Hase I, Morimoto K, Sakagami T, Kazumi Y, Ishii Y, van Ingen J. Disseminated Mycobacterium gordoniae and Mycobacterium lateum infection with elevated anti-IFN-γ neutralizing autoantibodies. J Infect Chemother. 2015;21(6):468–72.
16. Wu UI, Chuang YC, Sheng WH, Sun HY, Jhong YT, Wang JY, et al. Use of QuantIFERON-TB Gold In-tube assay in screening for neutralizing anti-interferon-γ autoantibodies in patients with disseminated nontuberculous mycobacterial infection. Clin Microbiol Infect. 2018;24(2):159–65.
17. Wu UI, Wang JT, Sheng WH, Sun HY, Cheng A, Hisu LY, et al. Incorrect diagnoses in patients with neutralizing anti-interferon-gamma-autoantibodies. Clin Microbiol Infect. 2020;26(12):1684.e1-e6.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.